GPBAR1 and Cholestatic liver disease: Studies have shown that TGR5 reduces ROS generation by inhibiting the NF-κB pathway and activating Nrf2/HO-1 signaling, promoting the expression of antioxidant enzymes and thus protecting against bile duct ligation-induced cholestatic liver disease [65].